Clinical / Pharmaceutical

Octreotide

Sandostatin · octreotide acetate · SMS 201-995

Somatostatin analog, FDA-approved 1988 (Sandostatin) for acromegaly and neuroendocrine tumors. Branded short-acting product is already a solution (50/100/500 mcg/mL ampuls). This leaf covers mcg reconstitution for compounded or lyophilized acetate vials. Sandostatin LAR is a depot — do not use this calculator for LAR kits.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: High1 peer-reviewed citation
Typical research dose
50-200 mcg SC 2–3×/day (labeled acromegaly/NET starting range; titrate)
Frequency
2–3× daily (short-acting SC); LAR is clinic-only
Half-life
~1.7–1.9 hours SC
Common vials
1 mg / 2 mg / 5 mg
CAS
83150-76-9
Molecular weight
~1019 Da (free peptide)
Dose it
2 mg + 2 mL BAC water → 1 mg/mL · 50 mcg ≈ 5 units (U-100)
Open in calculator

Mechanism of Action

Octreotide is a somatostatin analog (sst2/sst5). Sandostatin short-acting injection is already a solution (50/100/500 mcg/mL ampuls; multi-dose 200 and 1,000 mcg/mL). Plasma t½ ~1.7–1.9 hours; action can last up to ~12 hours.

This calculator is for lyophilized/compounded acetate vials in mg. Do not run LAR depot kits through it — LAR is a different reconstitution (milky suspension, gluteal, clinic).

Source: FDA Sandostatin label (DailyMed octreotide acetate)

Ampuls vs powder vs LAR

If you have a Sandostatin ampul, concentration is already on the label — skip powder math. If you have LAR, stop and use the LAR kit instructions. Powder math here is for compounded/lyophilized acetate.

Dosing Protocol

Typical Dose50-200 mcg SC 2–3×/day (labeled acromegaly/NET starting range; titrate)
Frequency2–3× daily (short-acting SC); LAR is clinic-only
Half-Life~1.7–1.9 hours (SC; duration of action up to ~12 h)
Common Vial Sizes1 mg, 2 mg, 5 mg

Dosing Protocols

Labeled short-acting (acromegaly/NET starting)

Dose
50–200 mcg
Frequency
2–3× daily SC
Note: Titrate per PI. This is not a research peptide protocol.

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 50–200 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)39 mcg96 mcg154 mcg
140 lb(63 kg)45 mcg113 mcg180 mcg
160 lb(73 kg)52 mcg130 mcg209 mcg
180 lb(82 kg)59 mcg146 mcg234 mcg
200 lb(91 kg)65 mcg163 mcg260 mcg
220 lb(100 kg)71 mcg179 mcg286 mcg
250 lb(113 kg)81 mcg202 mcg323 mcg

💉 For exact syringe units based on your vial concentration, use the Octreotide Reconstitution Calculator →

Administration

Route
Deep SC or IV (labeled). Short-acting is not LAR.
Timing
Follow the PI.
Fasting Required?
No — food timing not critical

Expected Timeline

Hours
GH/symptom control window up to ~12 h depending on tumor type (label).

Who Is It For?

Acromegaly / NETs

High

FDA-approved since 1988. This site does syringe math, not oncology.

Reconstitution Example

Vial
2 mg
Diluent
2 mL
Concentration
1 mg/mL
Per Unit (100u syringe)
10 mcg
Dose of 50 mcg = 5 units on a 100-unit insulin syringe
🧮 Calculate Your Exact Octreotide Dose →

Safety & Considerations

Prescription. Gallbladder disease, glucose dysregulation (hypo- and hyperglycemia), bradycardia, steatorrhea. Drug interactions (e.g. cyclosporine, insulin). LAR is a different product.

Regulatory & Legal Status

FDA Status (US)
Approved

FDA-approved 1988 as Sandostatin® (acromegaly, NETs). LAR depot is a separate clinic product

WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Prescription Drug

US Compounding: Available via licensed pharmacy Rx

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Octreotide— Dosing Guide
Dose Range
50-200 mcg SC 2–3×/day (labeled acromegaly/NET starting range; titrate)
Half-Life
~1.7–1.9 hours (SC; duration of action up to ~12 h)
Frequency
2–3× daily (short-acting SC); LAR is clinic-only
Route
Subcutaneous
1 mg vial2 mg vial5 mg vial
💧 2 mL BAC water📐 1 mg/mL💉 10 mcg/unit (100u syringe)
Clinical / Pharmaceuticalcalcmypeptide.com

Frequently Asked Questions

My vial is 500 mcg/mL already.▼
Then concentration is 500 mcg/mL. On U-100, 1 unit = 5 mcg. A 100 mcg dose is 20 units. Ignore the powder fields.
Is this tesamorelin’s opposite?▼
Roughly: octreotide suppresses GH; tesamorelin stimulates it. Different indications. Do not stack them as a DIY endocrine experiment.

References

  1. Novartis / FDA DailyMed “Sandostatin (octreotide acetate) injection label.” US PI (current).

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library